#China #Hangzhou #KRAS G12D #Ranok Therapeutics #RNK08954

Ranok Therapeutics Reports Positive Results for KRAS G12D Inhibitor RNK08954

Ranok Therapeutics, a biotechnology firm focused on developing novel cancer therapies, has announced the publication of its Phase 1a clinical study results for RNK08954. These findings, revealed in the peer-reviewed journal Cancer Discovery, demonstrate the drug's potential as an innovative oral treatment for patients with advanced solid tumors characterized by the KRAS G12D mutation.

Study Overview

The Phase 1a study aimed to assess the safety and tolerability of RNK08954 while establishing a recommended dose for future studies. Conducted at multiple sites in China, the research involved the evaluation of 36 patients who presented with various advanced solid tumors. The participants were monitored for both clinical activity and side effects during the study.

Results indicated an overall objective response rate (ORR) of 28% in the study population, an outcome that indicates the proportion of patients responding positively to the treatment. More importantly, for patients suffering from non-small cell lung cancer (NSCLC), the ORR was significantly higher at 58.33%, coupled with a 100% disease control rate (DCR). These response rates show considerable promise and confirm RNK08954's efficacy especially in NSCLC, which is a major concern in cancer care today.

Safety Profile of RNK08954

The safety profile of the treatment appears favorable, with predominantly Grade 1-2 gastrointestinal effects noted alongside a decreased appetite among participants. Notably, the treatment did not result in any dose-limiting toxicities throughout its administration. This clean safety profile is crucial for moving forward into subsequent phases of clinical trials.

Insights from the Principal Investigator

Professor Song Zhengbo, who serves as the Director of the Phase I Clinical Trial Unit at Zhejiang Cancer Hospital and the principal investigator of the study, expressed gratitude for the recognition of their significant research. He stated, “RNK08954 represents a critical advancement in targeted therapy for KRAS G12D mutations. The positive results not only expedite clinical translation but also provide essential data for future pivotal studies.”

Dr. Iman Elhariry, the Chief Medical Officer at Ranok Therapeutics, echoed this sentiment, highlighting the targeted nature of RNK08954. “The 58.33% response rate in the NSCLC cohort demonstrates that we are effectively hitting the Switch II pocket with high selectivity. Given these strong signals of clinical activity, we have initiated our Phase 1b expansion study to delve deeper into the drug's potential, both as a monotherapy and paired with other treatments across various cancers.”

Future Directions

In anticipation of the ongoing clinical developments, Dr. Weiwen, the Founder and CEO of Ranok Therapeutics, remarked that the progress achieved in the realm of KRAS inhibitors stems from over a decade of research in structural biology and medicinal chemistry. Dr. Weiwen expressed optimism about the potential of RNK08954 to meet the urgent needs of patients who currently have limited options for targeted therapies.

With these advancements, Ranok Therapeutics is firmly positioned to make impactful contributions to the field of oncology, paving the way for innovative treatments that could significantly enhance patient outcomes.

What is KRAS G12D?

The KRAS G12D mutation is prevalent in various solid tumors, particularly in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC). Historically labeled as